MoonLake Immunotherapeutics (MLTX) EBT (2021 - 2026)

MoonLake Immunotherapeutics' EBT history runs 6 years deep, the most recent figure standing at -$69.1 million for Q1 2026.

• In Q1 2026, EBT fell 70.98% year-over-year to -$69.1 million; the TTM figure through Mar 2026 stood at -$258.4 million (down 75.22% YoY), while the FY2025 annual figure was -$229.7 million, down 89.9% from the prior year.
• EBT for Q1 2026 stood at -$69.1 million, down from -$62.8 million in the prior quarter.
• The five-year high for EBT was -$7.8 million in Q4 2023, with the low at -$70.6 million in Q3 2025.
• The 5-year median for EBT is -$17.4 million (2022), against an average of -$31.1 million.
• Peak annual rise in EBT reached 69.32% in 2022, while the deepest fall reached 20705.61% in 2022.
• MoonLake Immunotherapeutics' EBT stood at -$16.5 million in 2022, then surged by 52.34% to -$7.8 million in 2023, then slumped by 491.0% to -$46.4 million in 2024, then sank by 35.41% to -$62.8 million in 2025, then fell by 10.06% to -$69.1 million in 2026.
• Business Quant data shows MLTX's EBT at -$69.1 million in Q1 2026, -$62.8 million in Q4 2025, and -$70.6 million in Q3 2025.